Growing Global Incidence of Diabetes
The escalating incidence of diabetes worldwide is a key driver for the glucose biosensors market. In 2021, an estimated 537 million people from the age group 20-79 years had diabetes worldwide, as estimated by the International Diabetes Federation (IDF), which is estimated to rise to 643 million by 2030 & 783 million by 2045. The immense patient population with this severe and increasing condition requires ongoing and precise glucose monitoring devices to enable proper disease management, thus driving the need for innovative biosensor technologies.
Technological Innovations and Miniaturization
Ongoing innovation in glucose biosensor technology, especially the miniaturization, accuracy, and non-invasiveness of these devices, drives the market growth. Advances in electrochemical and optical sensing technologies, as well as the implementation of AI & ML for predictive analytics, are making them more functional and user-friendly. Such innovation results in greater patient compliance & enhanced glycemic control, rendering biosensors a critical tool in contemporary diabetes management.
Increasing Demand for Continuous Glucose Monitoring (CGM) Systems
The propelling adoption of Continuous Glucose Monitoring (CGM) systems is a major opportunity. CGM systems provide instant glucose measurements, which facilitate proactive care and minimize the threat of hypoglycemic and hyperglycemic events. The Centers for Disease Control & Prevention (CDC) states that regular monitoring of glucose can dramatically improve A1C levels. With trigerring awareness for the advantages of real-time data compared to periodic random checks, and with technology developments that make CGMs cost-effective & widely accessible, their usage will see a rise, growing the market.
Growth in Non-Invasive Glucose Monitoring Technologies
Another area with potential for growth is the creation of non-invasive glucose monitoring technologies. Present research and development activities concentrate on biosensors that can measure glucose levels using different biological fluids like sweat, saliva, or tears. Should the non-invasive solutions be successfully commercialized, they have the potential to transform diabetes treatment by increasing users' comfort level and widening acceptability, especially among patients who are needle-phobic. This would greatly boost market penetration and adoption levels across multiple population segments, further driving growth in the global glucose biosensors market.
The following Key Market Indicators present a comprehensive overview of the social and economic landscape of the selected region, offering critical insights into market-specific trends and developments. These indicators, combined with data from government statistics, industry associations, and corporate sources, form the analytical foundation of NextGen Intelligence Stats' market models.
Aspects | Details |
Base Year
|
2024 |
Historic Data
|
2021-2023 |
Forecast Period
|
2025-2035 |
Regions & Countries Covered
|
North America (United States, Canada), Europe (Germany, France, Italy, United Kingdom, Spain, Rest of Europe), Asia Pacific (China, Japan, South Korea, India, Rest of Asia Pacific), Latin America (Brazil, Argentina, Rest of Latin America), Middle East& |
Companies Profiles
|
|
Segmentation Level Customization
|
Additional Segments and Sub Segment |
Company Level Customization
|
Market share analysis at country levels |
Country level Data Customization
|
Segmental volume analysis Pricing Analysis of Product Company Market Share |
October 2024: Dexcom has launched its new G7 CGM System in more European territories, such as France and Spain. This rollout is designed to bring the more compact, precise, and user-friendly G7 sensor to more individuals with diabetes, providing a 30-minute warm-up period and 10-day sensor wear.
August 2024: Abbott Laboratories has gained FDA clearance for its new FreeStyle Libre 2 iOS app, enabling users to have optional glucose alarms delivered directly to their iPhone without the need to scan the sensor. This feature is designed to give more convenience and peace of mind to people with diabetes.
June 2024: Medtronic plc launched the MiniMed™ 780G system with Guardian™ 4 sensor in a number of new international markets, such as Australia and New Zealand. The advanced insulin pump system includes a SmartGuard™ algorithm that automatically changes insulin delivery to prevent highs and lows, further improving automated insulin delivery for patients.
April 2024: Ascensia Diabetes Care has formed a collaboration with SocialDiabetes, a top digital health organization, to combine Ascensia's Contour blood glucose meters with the SocialDiabetes application. The collaboration is designed to offer users an integrated platform for managing their diabetes information and being in touch with healthcare providers.
The global market for glucose biosensors is dominated by a competitive landscape of a combination of multinational players and nimble innovative firms. Abbott's FreeStyle Libre, Dexcom's, F. Hoffmann-La Roche Ltd. (Accu-Chek), LifeScan (OneTouch), and Ascensia Diabetes Care (Contour) have solid positions with large distribution networks and a commitment to easy-to-use and low-cost devices. Smaller specialized companies such as Bioling Incorporated and PalmSens are adding market dynamism by emphasizing new sensor technology, including non-minimally invasive or non-invasive methods. Strategic alliances, partnerships, and mergers & acquisitions are typical approaches used by market players to increase product offerings, improve technological prowess, and expand regional reach in this changing market.
• Broadcom
• Trend Micro Incorporated
• Sophos Ltd.
• Microsoft
• AO Kaspersky Lab
• Panda Security
• F-Secure
• IBM Corporation
• McAfee, LLC.
• ESET, spol. s r.o.
• Cisco Systems, Inc.
• Bitdefender
• Others
The glucose biosensors market stood at USD 9.56 billion in 2024 and is expected to reach USD 24.08 billion by 3035, growing at a CAGR of 8.3%.
North America accounted for 31.8% share in the global glucose biosensors market in 2024.
1.1. Introduction
1.2. Report Description & Objective
1.3. Assumption And Limitation
2.1. Data Collection
2.2. Primary Research & Secondary Research
2.3. Bottom-Up Approach & Top-Down Approach
2.4. Market Analysis & Size Estimation
2.5. Quality Check & Final Review
3.1. Report Scope
3.2. Executive Summary
4.1. Top Trends To Watch
4.2. Top Strategies Followed By Key Players
4.3. Top Investment Pockets
5.1. Market Definition
5.2. Market Drivers
5.3. Market Restraints & Challenges
5.4. Market Opportunities
6.1. Porter’s Five Forces’ Analysis
6.2. Value Chain Analysis / Supply Chain Analysis
6.3. PESTLE Analysis
6.4. Regulatory Landscape
6.5. Pricing Analysis
7.1. Global Glucose Biosensors Market, By Type
7.2. Global Glucose Biosensors Market Attractiveness, By Type
7.2.1. CGM (Continuous Glucose Monitoring)
7.2.2. SMBG (Self-monitoring Blood Glucose)
8.1. Global Glucose Biosensors Market, By Technology
8.2. Global Glucose Biosensors Market Attractiveness, By Technology
8.2.1. Electrochemical Biosensor
8.2.2. Optical Biosensor
8.2.3. Others
9.1. Global Glucose Biosensors Market, By Control Method
9.2. Global Glucose Biosensors Market Attractiveness, By Control Method
9.2.1. Chemical
9.2.2. Physical
9.2.3. Biological
9.2.4. Others
10.1. Global Glucose Biosensors Market, By End Use
10.2. Global Glucose Biosensors Market Attractiveness, By End Use
10.2.1. Hospitals
10.2.2. Homecare
10.2.3. Diagnostic Center
11.1. Global Glucose Biosensors Market, By Geography
11.2. Global Glucose Biosensors Market Attractiveness, By Geography
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Middle East & Africa
11.2.5. Latin America
12.1. North America Market Overview, By Countries
12.2. Market Overview, By Type
12.3. Market Overview, By Type
12.3.1. United States
12.3.2. Canada
13.1. Europe Market Overview, By Countries
13.2. Market Overview, By Type
13.3. Market Overview, By Type
13.3.1. Germany
13.3.2. France
13.3.3. UK
13.3.4. Italy
13.3.5. Spain
13.3.6. Rest of Europe
14.1. Asia Pacific Market Overview, By Countries
14.2. Market Overview, By Type
14.3. Market Overview, By Type
14.3.1. India
14.3.2. China
14.3.3. Japan
14.3.4. South Korea
14.3.5. Rest of Asia Pacific
15.1. Middle East & Africa Market Overview, By Countries
15.2. Market Overview, By Type
15.3. Market Overview, By Type
15.3.1. GCC
15.3.2. South Africa
15.3.3. Rest of Middle East & Africa
16.1. South America Market Overview, By Countries
16.2. Market Overview, By Type
16.3. Market Overview, By Type
16.3.1. Brazil
16.3.2. Argentina
16.3.3. Rest of South America
17.1. Key Developments
17.1.1. Partnerships, Collaborations, Agreements
17.1.2. Mergers & Acquisitions
17.1.3. New Product Developments
17.1.4. Other Developments
17.2. Company Share Analysis
17.3. Company Profiles
17.3.1. Abbott Laboratories
17.3.1.1. Company Overview
17.3.1.2. Product Overview
17.3.1.3. Financial Insights
17.3.1.4. Recent Developments
17.3.1.5. SWOT Analysis
17.3.2. ACON Laboratories, Inc.
17.3.3. Ascenia Diabetes Care
17.3.4. Biolinq Incorporated
17.3.5. Dexcom
17.3.6. F. Hoffmann-La Roche Ltd.
17.3.7. Lifescan
17.3.8. Medtronic plc
17.3.9. PalmSens
17.3.10. SB Solutions
Data Collection
Primary Research & Secondary Research
Bottom-Up Approach & Top-Down Approach
Market Analysis & Size Estimation
Quality Check & Final Review
By Type
• CGM (Continuous Glucose Monitoring)
• SMBG (Self-monitoring Blood Glucose)
By Technology
• Electrochemical Biosensor
• Optical Biosensor
• Others
By Control Method
• Chemical
• Physical
• Biological
• Others
By End-Use
• Hospitals
• Homecare
• Diagnostic Center